Acsl1介导的脂肪酸合成损害1型糖尿病骨结合
该研究探讨1型糖尿病骨结合受损的机制,整合RNA-seq、代谢组学和ATAC-seq分析,发现严格血糖控制未能正常化脂肪酸生物合成过程。高血糖暴露通过巨噬细胞Acsl1位点H3K4me1表观修饰维持Acsl1转录,增强脂肪酸合成和促炎反应,加速破骨分化,损害骨修复。
要点
- 严格血糖控制不能完全恢复糖尿病骨结合
- Acsl1位点H3K4me1修饰介导训练免疫
- 靶向H3K4me1或Acsl1或可改善骨结合
核心结论
- 糖尿病诱导的Acsl1位点H3K4me1修饰驱动代谢重编程,构成训练免疫基础并导致骨损害。
- 靶向H3K4me1或Acsl1是改善糖尿病患者种植体骨结合和骨骼再生的潜在治疗策略。
研究设计与样本
- 研究整合RNA-seq、代谢组学和ATAC-seq分析,探讨1型糖尿病骨结合受损机制。
主要发现
- 严格血糖控制在1型糖尿病中未能正常化脂肪酸生物合成过程,该过程持续激活。
- 经历二次刺激时,持续激活的脂肪酸合成增强巨噬细胞介导的炎症和破骨细胞生成。
- 先前高血糖暴露增强染色质可及性,并通过巨噬细胞Acsl1位点H3K4me1表观修饰维持Acsl1转录。
- 该表观印记增强脂肪酸合成代谢,放大促炎细胞因子产生,加速破骨细胞分化,最终损害骨修复。
临床怎么用
- 提示即使严格控糖,糖尿病患者种植前仍需关注骨结合受损的潜在风险。
- 靶向H3K4me1或Acsl1可能成为改善糖尿病患者种植体骨结合的将来策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diabetes mellitus is considered a relative contraindication to oral implant therapy, as hyperglycemia frequently precipitates vascular and osseous pathologies. Although clinicians routinely prioritize glycemic control before initiating implant-related treatment plans, diabetic patients often exhibit impaired osseointegration. However, the specific mechanisms remain to be elucidated. Emerging evidence suggests that this refractory bone loss is mediated by trained immunity, a process in which innate immune cells retain an epigenetic memory of prior inflammatory stimuli and mount an exaggerated response upon secondary challenge such as the invasive implantation process or inflammatory insult. Here, integrating RNA-seq, metabolomics, and transposase-accessible chromatin using sequencing analyses, we demonstrate that stringent glycemic control in type 1 diabetes fails to normalize the fatty acid biosynthetic process, which remains persistently activated and potentiates macrophage-mediated inflammation and osteoclastogenesis when experiencing the secondary stimuli. Mechanistically, prior hyperglycemic exposure enhances chromatin accessibility while sustaining Acsl1 transcription by H3K4me1 epigenetic modification at the Acsl1 locus in macrophages. This epigenetic imprint augments fatty acid anabolism, amplifies proinflammatory cytokine production, and accelerates osteoclastic differentiation, ultimately compromising osseous repair. Collectively, our findings reveal that diabetes-induced H3K4me1 modification at Acsl1 drives metabolic reprogramming underpinning trained immunity and consequent bone damage. Targeting H3K4me1 or Acsl1 therefore represents a promising therapeutic strategy to improve implant osseointegration and skeletal regeneration in diabetic patients.
引用
- Zheng XH, Zhu XY, Chen X, et al. Acsl1-Mediated Fatty Acid Synthesis Impairs Osseointegration in Type 1 Diabetes. J Dent Res. 2026. PMID: 41902555. doi:10.1177/00220345261430286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。